Rodman & Renshaw Reiterates Market Underperform and PT of $13 on Medivation

by Emily Austin, Benzinga Staff Writer
August 11, 2011 2:57 AM | 14 seconds read |
Rodman & Renshaw reiterated its Market Underperform on Medivation MDVN. At the same time, the rating agency left its price target on the company's stock unchanged at $13. On Wednesday, MDVN lost 11.37% of its value to end the day at $15.36.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: ReiterationAnalyst RatingsHealth CareLife Sciences Tools & ServicesRodman and Renshaw
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!